Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Amyloid Plaque and Tangle Imaging in Aging and Dementia
This study is currently recruiting participants.
Verified by National Institute on Aging (NIA), August 2008
Sponsored by: National Institute on Aging (NIA)
Information provided by: National Institute on Aging (NIA)
ClinicalTrials.gov Identifier: NCT00355498
  Purpose

Amyloid senile plaques (SPs) and neurofibrillary tangles (NFTs) are neuropathological hallmarks of Alzheimer's disease (AD) that also accumulate in key brain regions in association with normal aging. This project will expand an established program in early detection and prevention of AD designed (1) to identify presymptomatic persons most likely to benefit from early intervention and (2) to provide an objective, noninvasive means to monitor therapeutic trials.


Condition
Memory Disorders
Alzheimer's Disease

Genetics Home Reference related topics: Alzheimer disease
MedlinePlus related topics: Alzheimer's Disease Dementia Memory
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Amyloid Plaque and Tangle Imaging in Aging and Dementia

Further study details as provided by National Institute on Aging (NIA):

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 194
Study Start Date: September 2005
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Controls
2
Mild Cognitive Impairment
3
Alzheimer's disease
4
FTD

Detailed Description:

A total of 194 volunteers will be recruited for this 2-year study. Participants will receive a baseline clinical and imaging evaluation and one follow-up evaluation two years later. These evaluations will include clinical and neuropsychological assessments, structural MRI and/or PET scans. Additional scans and scanning procedures will be performed on a subset of participants and participant visits, including serotonin density levels.

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The study population is selected from UCLA primary care clinics, UCLA memory clinic, residents from the California counties of Orange and Los Angeles who answer ads placed in newspapers in these areas.

Criteria

Inclusion Criteria:

  • Agreement to participate in a clinical and brain imaging study
  • Age 30 years or older
  • No significant cerebrovascular disease - modified Ischemic Score of ≤ 4
  • For volunteers with MCI or dementia, there must be a family member or potential caregiver available
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Screening laboratory tests and ECG without significant abnormalities that might interfere with the study.

Exclusion Criteria:

  • Evidence of neurologic or other physical illness that could produce cognitive deterioration; in addition to a physical and neurological examination, volunteers will be screened for Parkinson's disease
  • History of myocardial infarction within the previous year or unstable cardiac disease
  • Uncontrolled hypertension (systolic BP>170 or diastolic BP>100), history of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer
  • Major psychiatric disorders, such as bipolar disorder or schizophrenia
  • Because medications can affect cognitive functioning, volunteers needing medicines that could influence psychometric test results will be excluded; use of any of the following drugs will also exclude volunteers: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, benzodiazepines, systemic corticosteroids, and medications with significant cholinergic or anticholinergic effects, anti-convulsants, or warfarin
  • Current diagnosis or history of alcoholism or drug dependence
  • Evidence of untreated depression as determined by a HAM-D (Hamilton, 1960) score of ≥ 12 (17-item version) or untreated anxiety by a score of ≥ 8 on the Hamilton Anxiety Scale (HAM-A; Hamilton, 1959)
  • Use of any investigational drugs within the previous month or longer, depending on drug half-life
  • Contraindication for MRI scan (e.g., metal in body, claustrophobia)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00355498

Contacts
Contact: Andrea Kaplan 310-825-0545 akaplan@mednet.ucla.edu

Locations
United States, California
Jane & Terry Semel Institute for Neuroscience & Human Behavior Recruiting
Los Angeles, California, United States, 90024
Contact: Andrea Kaplan     310-825-0545     akaplan@mednet.ucla.edu    
Contact: Deborah Dorsey, RN, MN     310-825-0545     ddorsey@mednet.ucla.edu    
Sponsors and Collaborators
Investigators
Principal Investigator: Gary W. Small, MD University of California, Los Angeles, Neuropsychiatric Institute
  More Information

Publications:
Responsible Party: UCLA ( Gary Small, MD )
Study ID Numbers: IA0093, P01-AG024831-01
Study First Received: July 20, 2006
Last Updated: August 28, 2008
ClinicalTrials.gov Identifier: NCT00355498  
Health Authority: United States: Federal Government

Keywords provided by National Institute on Aging (NIA):
functional magnetic resonance imaging
positron emission tomography
beta-amyloid
tau

Study placed in the following topic categories:
Alzheimer Disease
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Memory Disorders
Cognition Disorders
Signs and Symptoms
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Neurologic Manifestations
Dementia
Neurobehavioral Manifestations
Delirium

Additional relevant MeSH terms:
Nervous System Diseases
Tauopathies

ClinicalTrials.gov processed this record on January 14, 2009